Drugs /

m1231

Back to Drugs List

Overview

NCI Definition [1]:
An antibody drug conjugate (ADC) composed of a bispecific antibody directed against the tumor associated antigens (TAAs) mucin-1 (MUC1) and human epidermal growth factor receptor (EGFR), conjugated, via a cleavable valine-citruline-based linker, to the hemiasterlin-related toxic warhead, with potential antineoplastic activity. Upon intravenous administration, the antibody moiety of anti-MUC1/EGFR bispecific ADC M1231 targets and binds to MUC1 and EGFR expressed on certain tumor cells. Upon binding, internalization, and enzymatic cleavage, the cytotoxic hemiasterlin moiety of M1231 binds to the vinca domain on tubulin, resulting in inhibition of tubulin polymerization and microtubule assembly, depolymerization of existing microtubules, inhibition of mitosis, and inhibition of cellular proliferation. MUC1 and EGFR, overexpressed on the surface of a variety of cancer cells, play key roles in tumor cell survival and proliferation. MUC1 and EGFR are often co-localized due to loss of membrane polarization on tumor cells while co-expression in normal cells is limited.

Clinical Trials

View Clinical Trials for m1231

M1231 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating m1231, 1 is phase 1 (1 open).

EGFR Expression and MUC1 Expression are the most frequent biomarker inclusion criteria for m1231 clinical trials.

Malignant solid tumor is the most common disease being investigated in m1231 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating M1231
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating m1231 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-muc1/egfr bispecific antibody drug conjugate m1231
Drug Target(s) [2]:
EGFR, MUC1
NCIT ID [1]:
C177111

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.